Treatment of organ transplantation rejection

A method of treating organ transplantation rejection in a mammal comprising administering to the mammal a synergistically effective amount of a combination of (a) at least one immunosuppressive agent, selected from the group consisting of cyclosporin A, azathioprine, FK506, mycophenolic acid or the morpholinethylester thereof, or rapamycin and (b) at least one compound of the formula:

• ##STR11## or a pharmaceutically acceptable salt thereof wherein:
• R.sup.1 is phenyl;
• phenyl substituted with one halogen;
• R.sup.3 is H or alkyl of 1 or 2 carbon atoms;
• R.sup.4 is H or alkyl of 1 or 2 carbon atoms;
• R.sup.4 is CO.sub.2 H, a sodium or potassium salt thereof;
• R.sup.5 and R.sup.6 are independently H, halogen, CH.sub.3 or CF.sub.3 ;
• R.sup.7 and R.sup.8 are independently H or halogen;
• provided that R.sup.5, R.sup.6 and R.sup.7 cannot all be H;
• and when R.sup.6 is CH.sub.3, then R.sup.7 cannot be Cl.

A method of treating organ transplantation rejection in a mammal comprising administering to the mammal a synergistically effective amount of a combination of (a) at least one immunosuppressive agent, selected from the group consisting of cyclosporin A, azathioprine, FK506, mycophenolic acid or the morpholinethylester thereof, or rapamycin, and (b) at least one compound of the formula:

• ##STR12## or a pharmaceutically acceptable salt thereof wherein:
• R.sup.1 is ##STR13## R.sup.3 is H or alkyl of 1 or 2 carbon atoms;
• R.sup.4 is CO.sub.2 H, a sodium or potassium salt thereof;
• R.sup.5 and R.sup.6 are independently H, halogen or CF.sub.3 provided that both R.sup.5 and R.sup.6 are not hydrogen;
• W and Z are independently H, halogen, alkyl of 1 to 5 carbon atoms or CF.sub.3.

A method of treating rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, myasthenia gravis, graft versus host disease, psoriasis, Crohn's disease, or primary biliary cirrhosis in a mammal comprising administering to the mammal a synergistically effective amount for the treatment of a desired aforesaid disease, a combination of (a) at least one immunosuppressive agent, selected from the group consisting of cyclosporin A, azathioprine, FK506, mycophenolic acid or the morphilinethylester thereof, or rapamycin, and (b) at least one compound of the formula:

• ##STR14## or a pharmaceutically acceptable salt thereof wherein:
• R is ##STR15## R.sup.1 is ##STR16## R.sup.3 is H, alkoxy of 1 to 3 carbon atoms, alkyl of 1 to 2 carbon atoms, or hydroxy;
• R.sup.4 is CO.sub.2 H;
• R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are independently H, F, Cl, Br, I, CH.sub.3, CF.sub.3, or alkyl of 1 to 3 carbon atoms, at least two of R.sup.5, R.sup.6, R.sup.7 and R.sup.8 being H;
• W, Y and Z are independently H, F, Cl, Br, alkyl of 1 to 5 carbon atoms, NO.sub.2, OH, CF.sub.3 or OCH.sub.3 ;
• with the following provisos:
• (1) R.sup.5, R.sup.6 and R.sup.7 cannot all be H;
• and
• (4) when R.sup.6 is CH.sub.3, then R.sup.7 cannot be Cl.